Clinical evaluation of methoximorpholino-doxorubicin (FCE 23762) in dogs with spontaneous malignancies |
| |
| Authors: | Sheafor S E Couto C G Ward H Essinger C Nicol S J |
| |
| Institution: | Department of Veterinary Clinical Sciences, Ohio State University, Columbus 43210, USA. |
| |
| Abstract: | We conducted a clinical evaluation of FCE 23762, a methoxymorpholino analog of doxorubicin, in 48 dogs with metastatic, nonresectable, or chemotherapy-resistant spontaneous malignancies at an initial dosage of 50-60 microg/kg IV every 3 weeks. Clinical evidence of toxicity was minimal; 6 dogs developed grades I, II, and III hematologic toxicities after the 1st treatment, and 1 dog developed grade II gastrointestinal toxicity. One dog became pancytopenic 4 months after discontinuation of FCE 23762. No other adverse effects were noted. Partial or complete remissions were observed in 32% of the dogs. Responses were observed both in previously untreated dogs and in those that had received prior chemotherapy, including doxorubicin. FCE 23762 is a promising new antineoplastic agent that can be used safely in dogs with cancer; doses higher than those used in this study may be used eventually in practice. |
| |
| Keywords: | Anticancer agents Chemotherapy Neoplasia Remission Toxicity |
| 本文献已被 PubMed 等数据库收录！ |
|
